Combination CurQD and Vedolizumab in Ulcerative Colitis

Study acronym: Curve UC
StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 1 → 4 locations
    • Eligibility criteria expanded, about 28 words
    • Secondary endpoints: details revised at 3 of 5 entries
  2. Start date: Jun 24, 2026 to Oct 1, 2026v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to test the efficacy and safety of the study intervention, CurQD or placebo (non-active pill), in combination with vedolizumab prescribed as standard of care for patients with ulcerative colitis (UC)..
Trial Details
NCT Number NCT07665294
Lead Sponsor Ryan C Ungaro
Collaborators: United States Department of Defense
Conditions
(from sponsor)		 Ulcerative Colitis
Related terms Colitis, Ulcerative
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov